PATIENT INFORMATION SHEET KEY FACTS

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "PATIENT INFORMATION SHEET KEY FACTS"

Transcription

1 PATIENT INFORMATION SHEET KEY FACTS Please read this carefully and refer to the full information sheet You are invited to take part in a research study, comparing subcutaneously (injection under skin) administered Kineret to standard treatment in patients who have had a subarachnoid haemorrhage. The study is being carried out by Dr Pippa Tyrrell, Consultant in Stroke Medicine together with your consultant and members of the research staff. If you consent to take part in the study you will:- o have a baseline assessment to confirm that you are eligible to take part in the study; this will be in addition to your standard care o be randomised to receive, either twice daily injections of Kineret as well as standard treatment or standard treatment and no study drug These will be for up to 21 days from the onset of the haemorrhage (or until discharge from hospital) o All patients will have samples of blood taken at pre-determined time points for up to 21 days (or discharge). These samples will be in addition to standard care o All patients will have assessments of their health at pre-determined time points for up to 21 days (or discharge). These will be in addition to standard care. Members of the research team will have access to your medical records during and after study participation. You will not benefit directly from taking part in the study and potential risks are explained You do not have to take part if you do not want to. You are free to withdraw from the study at any time and this will not affect the care you receive. We ask permission to keep blood samples for an indefinite period of time following the end of the study Please refer to full information sheet Thank you for your time Patient information sheet, Version 2 28/7/11 Page 1 of 9

2 Brain Injury Research Group Clinical Sciences Building, Salford Royal Foundation Trust, Stott Lane, Salford, M6 8HD Dr Pippa Tyrrell Mr Andrew King Mr James Galea Sharon Hulme Senior Lecturer in Stroke Medicine Consultant Neurosurgeon NIHR Fellow in Neurosurgery Research Nurse Telephone: Telephone: Telephone: An open-labelled study of the effect of subcutaneous, interleukin-1 receptor antagonist (Kineret ) on levels of inflammation following subarachnoid haemorrhage Short title: SC IL-1RA in SAH. REC Ref: 11/NW/0390 You are invited to take part in a study investigating how a potential treatment for brain injury works and acts in the body. You need to understand why the study is being done and what it will involve. Please take time to read this information. Talk to others about the study if you wish. The information sheet is divided into two parts: Part 1 why is the study being done and how will it affect you. Part 2 information in more detail. Please ask if you need more information. Take time to decide whether or not you wish to take part. What is the purpose of the study? After a subarachnoid haemorrhage (SAH) blood flow to the brain may be reduced, preventing oxygen from reaching brain tissue resulting in damage. This is known as cerebral ischaemia. Reduced blood flow may trigger symptoms similar to a stroke, which can be temporary or lead to long term disability. There are currently no treatments to reverse damage caused by cerebral ischaemia. We know that levels of inflammation within the body can influence the degree of cerebral ischaemia. Our research group has extensively investigated the use of a well-established anti-inflammatory drug Kineret in patients with brain haemorrhage. Kineret is similar to a naturally-produced protein, called interleukin-1 receptor antagonist (IL- 1Ra) and is already licensed to treat patients with rheumatoid arthritis. We have evidence from previous studies that Kineret reduces levels of inflammation in the body after SAH when given as a high dose infusion into a vein (intravenous). Kineret given at these levels are designed to treat any potential brain injury caused by cerebral ischaemia and in order to develop Kineret as a potential preventative therapy; we need to know its effect on levels of inflammation when given subcutaneously (injected into the skin) and using lower doses over a longer period of time. Patient information sheet, Version 2 28/7/11 Page 2 of 9

3 In order to do this, we plan to compare levels of inflammation in the blood of participants who have received subcutaneous injections of Kineret with those who have not. Why have I been asked to take part? You have suffered a subarachnoid haemorrhage (SAH). You are currently receiving medication to improve blood flow to your brain. However, this may not prevent cerebral ischaemia. Cerebral ischaemia leads to a risk of developing symptoms similar to a stroke e.g. limb weakness or difficulty with speech, so you will remain under the care of the neurosurgical team until you are discharged from hospital. We would like to conduct an assessment and obtain a blood sample each day for up to 21 days from onset of your symptoms (or earlier if you are discharged from hospital). You will also be randomised to receive either standard treatment plus Kineret twice-daily as a subcutaneous injection or standard treatment with no study drug. What is Kineret and how does it work? Kineret (approved name Anakinra) reduces inflammation in the injured brain. It has been given to thousands of patients with rheumatoid arthritis, to healthy volunteers and, in previous studies undertaken by our research group, to patients with SAH and stroke. Do I have to take part? No, you do not have to take part in this study. If you decide that you want to take part you will be given this information to keep and asked to sign a consent form. You are free to withdraw from the study at any time. You do not have to give a reason for doing so and this will not affect the care you receive. What will happen if I decide to take part? Members of the research team will perform an assessment to check that you are eligible to participate in the study and then will ask for your consent to participation. The research team will then contact an independent randomisation service for allocation of your study group. What is randomisation? Sometimes we don t know which way of treating patients is best. To find out, we need to compare different treatments. We put people into groups and give each group a different treatment and the results are compared. To try to make sure the groups are the same to start with, each patient is put into a group by chance (randomly). This selection will be done by a third-party (external service) so which group you are in will not be influenced by you or the researcher. In this study only half the participants will receive Kineret along with standard treatment, the others will receive standard treatment only. Patient information sheet, Version 2 28/7/11 Page 3 of 9

4 After you have been randomised, a sample of up to 20mls of blood (up to 4 teaspoons) will be taken to establish levels of inflammation within the blood. Some of this blood will be used for standard clinical investigations and where possible we will try to take research and clinical samples at the same time. If you have been randomised to receive Kineret, you will then be given twice daily injections (usually 7am and 7pm) for up to 21 days from the date of your SAH or until you are discharged from hospital. The research staff will also take samples of blood once a day over the same time period. You will also be assessed and observed carefully. If you are not randomised to receive Kineret, you will have only assessments and blood samples. Whenever possible, the blood will be taken from lines which are already in place as part of your routine care. The assessment on day of discharge (or day 21 after SAH) will record everything that has happened since you received Kineret as well as your current condition. You will be given a discharge pack containing contact details for the study team and a sheet in which to record any concerns you may have after discharge. You will be contacted by the research team 30 days from the date of your haemorrhage to discuss these issues and again at six months to record your progress and recovery. With your permission, we would like to contact your family doctor (GP), Consultant and any other Health Care Professional involved in your care to let them know that you have been a volunteer. We may also ask them for medical information about you. Are there any alternative treatments? No, there are no current alternative treatments. What are the possible benefits of taking part? The study will not have any direct benefits to you but you will be helping to increase what is known about subarachnoid haemorrhage and the development of new treatments. What are the possible risks/side effects of taking part? Your well being and safety is our first concern. Most of the information about the side effects of Kineret has been discovered from the treatment of patients with rheumatoid arthritis; many of whom have taken Kineret for a long time (months or years). The intervention period for this study is much shorter (maximum of 21 days). In studies that have given Kineret over short periods (for severe infections; subarachnoid haemorrhage or stroke) there has been no evidence of increased infections however, studies in patients with rheumatoid arthritis who have been on long term Kineret have shown a small possibility of an increased risk of infections; some of which are classed as serious. Patient information sheet, Version 2 28/7/11 Page 4 of 9

5 Previous studies also showed that after long-term use of Kineret the body may make antibodies to IL-1Ra (found in Kineret) with a possible risk of allergy. This is a rare but a potentially serious side effect. If you think you may have received Kineret or Anakinra, or a similar drug either as part of your general care or as part of another research study, you may be excluded from taking part in this study. The researcher will be happy to discuss this issue. Headache and nausea are common side effects of subarachnoid haemorrhage. They have also been reported after Kineret by patients with rheumatoid arthritis. Medications to alleviate headache and nausea are already part of your standard care. You may experience some discomfort and bruising caused by blood sampling, when existing lines are not available. We will try to combine clinical and research blood sampling to minimise your discomfort. We do not anticipate any side effects from this study, but if any adverse effects are seen the study intervention will be stopped immediately. Withdrawal from the study If you, your representative, or the doctors responsible for your clinical care choose to withdraw you from the study after receiving Kineret, you will be asked if the research team can complete an end of study assessment. If possible a final sample of blood will be taken. We will continue to monitor your progress using information obtained as part of standard clinical care and no further samples will be taken. The study team may withdraw participants if they consider it to be in their best interests. Pregnancy The effects of Kineret on the foetus and nursing child are not known. If you suspect or know you are pregnant or are breast-feeding you cannot take part in the study. Will I be paid for taking part? You will not receive payment for taking part in the study. Researchers working on the study are funded by the Medical Research Council or the University of Manchester and will receive no extra remuneration as a result of your participation. THIS COMPLETES PART 1 OF THE INFORMATION SHEET Patient information sheet, Version 2 28/7/11 Page 5 of 9

6 PART 2 What if new information becomes available? Sometimes during the course of a project, new information becomes available relating to what is being studied. If this happens, a researcher will tell you about it and discuss if you want to continue in the study. You may be asked to confirm your willingness to continue by signing a new consent form. What if there is a problem? This is very unlikely. In the event that something does go wrong and you are harmed there are no special compensation arrangements. If this is due to someone s negligence you may have grounds for a legal action for compensation against Salford Royal Foundation NHS Trust but you may have to pay your legal costs. The normal National Health Service complaints mechanisms will still be available to you. The study is being conducted by members of staff from the University of Manchester and will be covered by their institution s no fault compensation policy. Complaints. If you have concerns about any aspect of the study, you should speak to the researcher who will do their best to answer your question. Alternatively, you can contact Rachel Georgiou, Research and Development Directorate, Salford Royal NHS Foundation Hospital, 544 Eccles New Road, Salford, Tel Confidentiality. If you decide to take part your hospital notes and other health records may be seen by authorised people (other researchers and people checking the study conduct). Your name will not appear in any publications arising from the study. What will happen to the results of the study? The results of the study will be submitted for publication to medical journals and at conferences. The results will also be submitted to authorities within the United Kingdom who are responsible for the development of new drugs to ensure they have all relevant information about the study drug and the conduct of the study. If you wish, we can send you a summary of the study findings but this may not be for some time. Storage of blood samples and usage. With your permission we would like to treat the blood samples that you give as a gift to allow further investigation of subarachnoid haemorrhage, brain injury, inflammation, drug development and other related disorders; as well as checking the quality of our current tests and development of new ones. Patient information sheet, Version 2 28/7/11 Page 6 of 9

7 We would also like to be able to use remaining components of the sample given to check the quality of the tests we carry out and develop new tests. You are under no obligation for your samples to be used in this way. You will be asked to sign a consent form to allow your samples to be used for these purposes. Samples would only be used for research relating to brain injury, inflammation, drug development and other related disorders. You are under no obligation for your samples to be used in this way. You will be asked to sign a consent form to allow your samples to be used for the purposes stated above. Data storage and usage. The study will confirm the safety of giving Kineret as a subcutaneous injection to patients with subarachnoid haemorrhage, therefore if you decide to withdraw from the study we will need to keep the information that we have obtained from you already. In order to ensure we have an accurate record of your history and clinical presentation, we will also need to access your clinical records, regardless of whether you are randomised to receive Kineret. Anonymised data will also be shared by members of the research team based within the University of Manchester. All clinical information will be anonymised before it is stored. The study is funded by the Medical Research Council. As such we will be following the Council s guidelines regarding the sharing of study data. This means that the anonymised data from the study will be available to others. The data and information from the study will be stored for up to 20 years. Organisation of the study The study is organised by the Brain Injury Research Group at Salford Royal Foundation NHS Trust and The University of Manchester. Who has reviewed the study? The study has been reviewed by and has received a favourable opinion from North West 6 REC GM South Research Ethics Committee and approval from the Medicines and Healthcare Regulatory Agency. Contact for further information: If you have any queries or questions relating to the study please ask the unit staff to contact: Sharon Hulme, Senior Research Nurse, Tel: or study mobile: James Galea, Clinical Research Fellow, Thank you for your time. Patient information sheet, Version 2 28/7/11 Page 7 of 9

8 PARTICIPANT CONSENT REC Ref No: 11/NW/0390 Title of Project: An open-labelled study of the effect of subcutaneous, interleukin-1 receptor antagonist (Kineret ) on levels of inflammation following subarachnoid haemorrhage Name of Lead Investigator: Dr Pippa Tyrrell Please initial box I confirm that I have read the information sheet dated 28/7/11 (version 2) and have had the opportunity to ask questions I understand that my participation is voluntary and that I am free to withdraw at any time, without giving any reason, without my medical care or legal rights being affected. I understand that sections of any of my medical notes may be looked at by responsible individuals from The Brain Injury Research Group, Salford Royal NHS Foundation Trust or from regulatory authorities where it is relevant to my taking part in research. I give permission for these individuals to have access to my records. I understand that the research team may wish to contact my GP other health care providers to inform them of my participation in the study and also to ask for information about my health. I agree that they can do this. I understand that anonymised data from the study will be made available to others in accordance with Medical Research Council guidelines. I understand that should I choose to withdraw from the study, members of the research team may continue to monitor my progress using information from my clinical notes. I give permission for these individuals to access my records I agree to take part in the above study. Patient information sheet, Version 2 28/7/11 Page 8 of 9

9 Name of research subject Date Signature (Please print) Name of Witness to Signature Date Signature (Must not be a member of the research team) Please print Member of research team member Date Signature Please print SAMPLE STORAGE CONSENT I agree that the sample(s) I have given and the information gathered about me can be stored by Dr Steve Hopkins and The Brain Injury Research Group at The University of Manchester for use in possible future projects for an indefinite time period, as described in the attached information sheet. I understand that some of these projects may be carried out by researchers other than those currently working with The Brain Injury Research Group who ran the first project. I agree that any remaining components of the blood sample may be used in the future for research relating to brain injury, inflammation, drug development and other related disorders. It may also be used for laboratory quality control and development purposes. Please initial box Name of research subject Date Signature (Please print) Name of Witness to Signature Date Signature (Must not be a member of the research team) Please print Member of research team member Date Signature Please print 3 copies required: top copy for researcher; one copy for patient; one copy to be kept with research participants notes Do you wish to receive information about the results of this study? Yes/No please circle Patient information sheet, Version 2 28/7/11 Page 9 of 9

Patient Information Leaflet: Part 1 select-d

Patient Information Leaflet: Part 1 select-d Patient Information Leaflet: Part 1 select-d Anticoagulation Therapy in SELECTeD Cancer Patients at Risk of Recurrence of Venous Thromboembolism Introduction This

More information

1. Study title Is the title self explanatory to a layperson? If not, a simplified title should be included.

1. Study title Is the title self explanatory to a layperson? If not, a simplified title should be included. These guidelines apply to all research projects where human subjects are involved in the study GUIDELINES FOR RESEARCHERS PATIENT INFORMATION SHEET & CONSENT FORM The guidance, which follows, applies primarily

More information

PARTICIPANT INFORMATION SHEET FEASIBILITY TRIAL Final Version 1.1:

PARTICIPANT INFORMATION SHEET FEASIBILITY TRIAL Final Version 1.1: PARTICIPANT INFORMATION SHEET FEASIBILITY TRIAL Final Version 1.1: 10.10.13 Title of Study: FRESH: Facilitating Return to work through Early Specialist Health-based interventions. (Working After Brain

More information

Add-Aspirin Clinical Trial We are inviting you to take part in a research study called the Add-Aspirin trial

Add-Aspirin Clinical Trial We are inviting you to take part in a research study called the Add-Aspirin trial (To be presented on local headed paper) Version 4.0, 11-Nov-2014 Add-Aspirin Clinical Trial We are inviting you to take part in a research study called the Add-Aspirin trial Before you decide whether to

More information

INTERBIO 21st FETAL & INFANT GROWTH STUDY

INTERBIO 21st FETAL & INFANT GROWTH STUDY REC reference 08/H0606/139 V.4 22.5.12 The International Fetal and Newborn Growth Standards for the 21st Century INTERBIO 21st FETAL & INFANT GROWTH STUDY PATIENT INFORMATION SHEET We would like to invite

More information

PATIENT INFORMATION SHEET. Version 5, March 2015

PATIENT INFORMATION SHEET. Version 5, March 2015 King s College Hospital NHS Foundation Trust King s College Hospital Denmark Hill London SE5 9RS Tel: 020 3299 9000 Fax: 020 3299 3445 www.kch.nhs.uk PATIENT INFORMATION SHEET Version 5, March 2015 Study

More information

U.K. Familial Ovarian Cancer Screening Study (UK FOCSS) Phase 2 Patient Information Sheet

U.K. Familial Ovarian Cancer Screening Study (UK FOCSS) Phase 2 Patient Information Sheet U.K. Familial Ovarian Cancer Screening Study (UK FOCSS) Phase 2 Patient Information Sheet 1. Invitation You are being invited to take part in a research study. Before you decide it is important for you

More information

PATIENT INFORMATION SHEET Study name: CT morphology of lung parenchyma pre and post bariatric surgery: correlation with pulmonary function.

PATIENT INFORMATION SHEET Study name: CT morphology of lung parenchyma pre and post bariatric surgery: correlation with pulmonary function. Version 2. 8.09.2011 Hammersmith Hospital Du Cane Rd London W12 0HS Tel: 020 8383 1000 www.imperial.nhs.uk PATIENT INFORMATION SHEET Study name: CT morphology of lung parenchyma pre and post bariatric

More information

RESEARCH PARTICIPANT INFORMATION SHEET. Safer pre-natal diagnosis using free DNA in maternal blood test. (also known as the IONA Study)

RESEARCH PARTICIPANT INFORMATION SHEET. Safer pre-natal diagnosis using free DNA in maternal blood test. (also known as the IONA Study) RESEARCH PARTICIPANT INFORMATION SHEET Safer pre-natal diagnosis using free DNA in maternal blood test (also known as the IONA Study) REC ref: 07/H0607/101 Principal Investigator: Mr Edward Johnstone Version

More information

Participant Information Sheet/Consent Form. Norfolk & Norwich University Hospital NHS Foundation Trust. Marc Moncrieff

Participant Information Sheet/Consent Form. Norfolk & Norwich University Hospital NHS Foundation Trust. Marc Moncrieff Participant Information Sheet/Consent Form Norfolk & Norwich University Hospital NHS Foundation Trust Short Title The Melanoma Margins Trial (MelMarT) Title A Phase III, Multi-centre Randomised Control

More information

Family Focused Therapy for Bipolar Disorder (Clinical Case Series) Participant Information Sheet

Family Focused Therapy for Bipolar Disorder (Clinical Case Series) Participant Information Sheet Family Focused Therapy for Bipolar Disorder (Clinical Case Series) Participant Information Sheet Study Title: Family Focused Therapy for Bipolar Disorder: A Clinical Case Series) We would like to invite

More information

Immune Cell Studies in Type 1 Diabetes (ISTID) INFORMATION SHEET FOR ADULTS WITH NEWLY- DIAGNOSED DIABETES. Sponsored by Cardiff University

Immune Cell Studies in Type 1 Diabetes (ISTID) INFORMATION SHEET FOR ADULTS WITH NEWLY- DIAGNOSED DIABETES. Sponsored by Cardiff University Immune Cell Studies in Type 1 Diabetes (ISTID) INFORMATION SHEET FOR ADULTS WITH NEWLY- DIAGNOSED DIABETES Sponsored by Cardiff University Chief Investigator Wales: Professor Colin Dayan Address: Centre

More information

AIR. Ankle Injury Rehabilitation. Chief Investigator: Dr Rebecca Kearney PATIENT INFORMATION SHEET

AIR. Ankle Injury Rehabilitation. Chief Investigator: Dr Rebecca Kearney PATIENT INFORMATION SHEET AIR Ankle Injury Rehabilitation Chief Investigator: Dr Rebecca Kearney PATIENT INFORMATION SHEET We would like to invite you to take part in our research study, investigating two different treatments for

More information

Information about the research

Information about the research Information about the research Health beliefs in OCD participants with OCD information sheet (non-nhs participants version) We would like to invite you to take part in our research study. The study is

More information

Biologic Treatments for Rheumatoid Arthritis

Biologic Treatments for Rheumatoid Arthritis Biologic Treatments Rheumatoid Arthritis (also known as cytokine inhibitors, TNF inhibitors, IL 1 inhibitor, or Biologic Response Modifiers) Description Biologics are new class of drugs that have been

More information

The RADICALS trial Radiotherapy Timing Randomisation (RADICALS-RT) Clinical trial of treatment after surgery for prostate cancer

The RADICALS trial Radiotherapy Timing Randomisation (RADICALS-RT) Clinical trial of treatment after surgery for prostate cancer Stoke Mandeville Hospital Mandeville Road Aylesbury Buckinghamshire HP21 8AL Tel: 01296 315 908 www.buckshealthcare.nhs.uk The RADICALS trial Radiotherapy Timing Randomisation (RADICALS-RT) Clinical trial

More information

Information about the research

Information about the research Information about the research Health beliefs in OCD participants with OCD information sheet (Non-qualitative interview version) We would like to invite you to take part in our research study. The study

More information

PATIENT INFORMATION SHEET

PATIENT INFORMATION SHEET PATIENT INFORMATION SHEET Surgical and large bore pleural procedures in Malignant pleural Mesothelioma And Radiotherapy Trial (SMART trial) Stoke Mandeville Hospital Mandeville Road Aylesbury Buckinghamshire

More information

Taking Part in Research at University Hospitals Birmingham

Taking Part in Research at University Hospitals Birmingham University Hospitals Birmingham NHS Foundation Trust The Trust provides free monthly health talks on a variety of medical conditions and treatments. For more information visit www.uhb.nhs.uk or call 0121

More information

Understanding Clinical Trials

Understanding Clinical Trials Understanding Clinical Trials The UK Clinical Research Collaboration (UKCRC) is a partnership of organisations working to establish the UK as a world leader in clinical research, by harnessing the power

More information

PARTICIPANT INFORMATION

PARTICIPANT INFORMATION PARTICIPANT INFORMATION IMPERIAL POPULATION BIORESOURCE TISSUE BANK (PART OF NIHR BIORESOURCE) In the UK around 20 million people are said to be living with a long-term condition such as diabetes or heart

More information

Excision of Epididymal Cyst

Excision of Epididymal Cyst Excision of Epididymal Cyst Patient Information Day Surgery Ward 3, Leigh Infirmary Author ID: LS Leaflet Number: SW3 011 Version: 5 Name of Leaflet: Excision of Epididymal Cyst Date Produced: April 2015

More information

Participant Invitation and Information Sheet MRI Test Run

Participant Invitation and Information Sheet MRI Test Run ON QE TRUST HEADED PAPER A randomised controlled trial of bariatric surgery versus a community weight loss programme for the sustained treatment of Idiopathic Intracranial Hypertension: the IIH:WT Trial

More information

Package leaflet: Information for the patient. Naloxone Hydrochloride 20 micrograms / ml Solution for Injection Naloxone hydrochloride

Package leaflet: Information for the patient. Naloxone Hydrochloride 20 micrograms / ml Solution for Injection Naloxone hydrochloride A leaflet will be included in each pack. The leaflet will consist of a Technical Information Leaflet and a Patient Information Leaflet. The two leaflets will be easily separatable. The text of the Technical

More information

If you are signing for a minor child, you refers to your child throughout the consent document.

If you are signing for a minor child, you refers to your child throughout the consent document. CONSENT TO PARTICIPATE IN A CLINICAL RESEARCH STUDY Adult Patient or Parent, for Minor Patient INSTITUTE: National Cancer Institute PRINCIPAL INVESTIGATOR: Raffit Hassan, M.D. STUDY TITLE: Tissue Procurement

More information

RESEARCH SUBJECT INFORMATION AND CONSENT FORM

RESEARCH SUBJECT INFORMATION AND CONSENT FORM 1 1 1 1 1 1 1 0 1 0 1 0 RESEARCH SUBJECT INFORMATION AND CONSENT FORM TITLE: PROTOCOL NR: SPONSOR: INVESTIGATOR: WIRB VCU tracking number This template is based on a drug or device research study. The

More information

Medical Research. General Information for Research Participants

Medical Research. General Information for Research Participants Medical Research General Information for Research Participants Contents Introduction 5 Medical research 6 What is a medical research? Who is classified as a research participant? Who conducts the research?

More information

[Informed Consent Form for ] Name the group of individuals for whom this consent is written. Explanation Example

[Informed Consent Form for ] Name the group of individuals for whom this consent is written. Explanation Example [YOUR INSTITUTIONAL LETTERHEAD] Please do not submit consent forms on the WHO letter head [Name of Principle Investigator] [Informed Consent Form for ] Name the group of individuals for whom this consent

More information

Beta-HCG monitoring What is it for?

Beta-HCG monitoring What is it for? Beta-HCG monitoring What is it for? Brooke Building Early Pregnancy Unit All Rights Reserved 2014. Document for issue as handout. Introduction This booklet aims to give some information and advice about

More information

Patient Handbook on Stem Cell Therapies

Patient Handbook on Stem Cell Therapies Patient Handbook on Stem Cell Therapies Appendix I of the Guidelines for the Clinical Translation of Stem Cells www.isscr.org 2008, International Society for Stem Cell Research 2 Introduction We have all

More information

CT scan. Turnberg Building Radiology

CT scan. Turnberg Building Radiology CT scan Turnberg Building Radiology 1 0161 206 1233 All Rights Reserved 2015. Document for issue as handout. What is a CT Scan? CT stands for Computed Tomography. A CT scan is a type of x-ray examination

More information

APPENDIX B SAMPLE INFORMED CONSENT FORM

APPENDIX B SAMPLE INFORMED CONSENT FORM APPENDIX B SAMPLE INFORMED CONSENT FORM B.1 INFORMED CONSENT TO PARTICIPATE IN A RESEARCH STUDY Umbilical Cord Blood Banking for Transplantation You are being asked to take part in a research study that

More information

Clinical Research at Leeds Teaching Hospitals NHS Trust

Clinical Research at Leeds Teaching Hospitals NHS Trust The Leeds Teaching Hospitals NHS Trust n Clinical Research at Leeds Teaching Hospitals NHS Trust Information for patients Research at Leeds Teaching Hospitals The Trust s ambition is to be a global leader

More information

APPENDIX I-A: INFORMED CONSENT BB IND 11184 Protocol CDC IRB #4167

APPENDIX I-A: INFORMED CONSENT BB IND 11184 Protocol CDC IRB #4167 APPENDIX I-A: INFORMED CONSENT BB IND 11184 Protocol CDC IRB #4167 INFORMED CONSENT FOR USE OF DIPHTHERIA ANTITOXIN (DAT) FOR SUSPECTED DIPHTHERIA CASES Investigational New Drug (IND) BB 11184 Protocol

More information

Lumbar Epidural. Patient Information. Pain Department

Lumbar Epidural. Patient Information. Pain Department Lumbar Epidural Patient Information Pain Department Author ID: SD Leaflet Number: Pain 016 Version: 6 Name of Leaflet: Lumbar Epidural Date Produced: May 2016 Review Date: May 2018 Lumbar Epidural Page

More information

ORAL ANTICOAGULANTS APIXABAN (ELIQUIS ) FOR ATRIAL FIBRILLATION

ORAL ANTICOAGULANTS APIXABAN (ELIQUIS ) FOR ATRIAL FIBRILLATION ORAL ANTICOAGULANTS APIXABAN (ELIQUIS ) FOR ATRIAL FIBRILLATION Information Leaflet Your Health. Our Priority. Page 2 of 6 What Are Anticoagulants And What Do They Do? This information leaflet has been

More information

You can also get the information in this booklet from a series of short videos from our website:

You can also get the information in this booklet from a series of short videos from our website: Patient Information You can also get the information in this booklet from a series of short videos from our website: http://www.lothiansexualhealth.scot.nhs.uk/pregnancy/termination/pa ges/default.aspx

More information

CORD BLOOD TRANSPLANTATION STUDY EXPANDED ACCESS PROTOCOL APPENDIX A SAMPLE CONSENT FORM

CORD BLOOD TRANSPLANTATION STUDY EXPANDED ACCESS PROTOCOL APPENDIX A SAMPLE CONSENT FORM APPENDIX A SAMPLE CONSENT FORM CORD BLOOD TRANSPLANTATION (COBLT) STUDY SAMPLE CONSENT FORM FOR THE EXPANDED ACCESS PROTOCOL You (your child) are being asked to take part in a clinical research study.

More information

Thank you for your interest in the Abu Dhabi Cohort Study.

Thank you for your interest in the Abu Dhabi Cohort Study. Thank you for your interest in the Abu Dhabi Cohort Study. You are being invited to join a medical research study on the causes and prevention of obesity, diabetes and heart disease among the Emirati national

More information

PRISM: PROGESTERONE IN EARLY PREGNANCY BLEEDING

PRISM: PROGESTERONE IN EARLY PREGNANCY BLEEDING Participant Information Sheet PRISM: PROGESTERONE IN EARLY PREGNANCY BLEEDING TRIAL CO-ORDINATOR Name: Adam Devall Telephone: 0121 623 6835 Email: prism@trials.bham.ac.uk This study is being funded by

More information

Research Ethics Review Committee (WHO ERC)

Research Ethics Review Committee (WHO ERC) Research Ethics Review Committee (WHO ERC) 20, AVENUE APPIA CH-1211 GENEVA 27 SWITZERLAND HTTP://INTRANET.WHO.INT/HOMES/RPC/ERC HTTP://WWW.WHO.INT/RPC/RESEARCH_ETHICS Informed Consent Template for Clinical

More information

MEDICATION GUIDE. ACTEMRA (AC-TEM-RA) (tocilizumab) Solution for Intravenous Infusion

MEDICATION GUIDE. ACTEMRA (AC-TEM-RA) (tocilizumab) Solution for Intravenous Infusion MEDICATION GUIDE ACTEMRA (AC-TEM-RA) (tocilizumab) Solution for Intravenous Infusion ACTEMRA (AC-TEM-RA) (tocilizumab) Injection, Solution for Subcutaneous Administration Read this Medication Guide before

More information

ASSESSMENT OF MAGNETIC RESONANCE IMAGING PROTOCOLS WITH HEALTHY VOLUNTEERS

ASSESSMENT OF MAGNETIC RESONANCE IMAGING PROTOCOLS WITH HEALTHY VOLUNTEERS SHEFC BRAIN IMAGING RESEARCH CENTRE FOR SCOTLAND Department of Clinical Neurosciences The University of Edinburgh Western General Hospital Crewe Road Edinburgh EH4 2XU Tel: 0131 537 2664 Fax: 0131 537

More information

University of California, Los Angeles CONSENT TO PARTICIPATE IN RESEARCH. A phase II trial on rizatriptan for Vestibular Migraine

University of California, Los Angeles CONSENT TO PARTICIPATE IN RESEARCH. A phase II trial on rizatriptan for Vestibular Migraine University of California, Los Angeles CONSENT TO PARTICIPATE IN RESEARCH A phase II trial on rizatriptan for Vestibular Migraine Robert W. Baloh, M.D. from the Department of Neurology at the University

More information

Treating varicose veins with foam injections using ultrasound guidance

Treating varicose veins with foam injections using ultrasound guidance Issue date February 2013 Information for the public NICE interventional procedures guidance advises the NHS on when and how new procedures can be used in clinical practice. Treating varicose veins with

More information

Infliximab is used to treat psoriasis, psoriatic arthritis, and several other inflammatory conditions, including other inflammatory skin diseases.

Infliximab is used to treat psoriasis, psoriatic arthritis, and several other inflammatory conditions, including other inflammatory skin diseases. INFLIXIMAB What are the aims of this leaflet? This leaflet has been written to help you understand more about the medication infliximab. It tells you what it is, how it works, how it is used to treat skin

More information

Fostair Maintenance & Reliever Therapy (MART) for asthma

Fostair Maintenance & Reliever Therapy (MART) for asthma Fostair Maintenance & Reliever Therapy (MART) for asthma Turnberg Building Respiratory Medicine 0161 206 3158 All Rights Reserved 2014. Document for issue as handout. Name: Date: Best peak flow recording

More information

FREQUENTLY ASKED QUESTIONS ORGAN DONATION NHS BLOOD AND TRANSPLANT

FREQUENTLY ASKED QUESTIONS ORGAN DONATION NHS BLOOD AND TRANSPLANT FREQUENTLY ASKED QUESTIONS ORGAN DONATION NHS BLOOD AND TRANSPLANT Would you take an organ if you needed one? Nearly everyone would. But only 32% of the UK population have joined the NHS Organ Donor Register.

More information

Package leaflet : information for the user. Dilute Adrenaline/Epinephrine Injection 1:10,000 adrenaline (epinephrine) (as acid tartrate) 0.

Package leaflet : information for the user. Dilute Adrenaline/Epinephrine Injection 1:10,000 adrenaline (epinephrine) (as acid tartrate) 0. Package leaflet : information for the user Dilute Adrenaline/Epinephrine Injection 1:10,000 adrenaline (epinephrine) (as acid tartrate) 0.1mg per ml Because of your condition it may not be possible for

More information

Publications Gateway Ref No Patient Online: OFFERING PATIENT ACCESS TO DETAILED ONLINE RECORDS

Publications Gateway Ref No Patient Online: OFFERING PATIENT ACCESS TO DETAILED ONLINE RECORDS Publications Gateway Ref No. 04367 Patient Online: TO DETAILED PATIENT ACCESS Equality and Health Inequalities Statement Promoting equality and addressing health inequalities are at the heart of NHS England

More information

Consultant Psychiatrist, Substance Misuse Services

Consultant Psychiatrist, Substance Misuse Services PATIENT GROUP DIRECTION (PGD) FOR THE ADMINISTRATION OF HEPATITIS A VACCINE (AVAXIM VACCINE) BY REGISTERED NURSES WORKING IN THE COMMUNITY SUBSTANCE MISUSE TEAMS Version Number : 4 Patient Group Direction

More information

CONSENT FORM 12/19/08

CONSENT FORM 12/19/08 12/19/08 1001 University Place Evanston, Illinois 60201 www.northshore.org CONSENT FORM Phone (224) 364-7100 Fax (847) 570-8011 Intravesical Alkalized Lidocaine for the Treatment of Overactive Bladder

More information

Clinical Trials Patient-Education Brochure

Clinical Trials Patient-Education Brochure Release Date November 2005 Revised January 2008 Revised March 2012 Clinical Trials Patient-Education Brochure American Society of Transplantation 1120 Route 73, Suite 200 Mount Laurel, NJ 08054 Phone:

More information

I B2.4. Design of the patient information leaflet for VariQuin

I B2.4. Design of the patient information leaflet for VariQuin (English translation of official Dutch version) I B2.4. Design of the patient information leaflet for VariQuin Information for the Patient: Read this package leaflet carefully when you have some time to

More information

Information for Egg Donors for Research

Information for Egg Donors for Research Newcastle Fertility Centre at BioScience Centre, International Centre for Life Times Square, Newcastle upon Tyne, NE1 4EP Telephone: 0191 2138213 Fax: 0191 2138124 www.nfc-life.org.uk Information for Egg

More information

Pl"OtocolDirector: Iris Schrijver _ IRB Approval Date: _June 20 2006 IRE Expiration Date: June 19, 2007 _ STANFORD SAMPLE CONSENT FORM

PlOtocolDirector: Iris Schrijver _ IRB Approval Date: _June 20 2006 IRE Expiration Date: June 19, 2007 _ STANFORD SAMPLE CONSENT FORM Protocol Title: Molecular genetic basis of sensorineural hearing Pl"OtocolDirector: Iris Schrijver IRB Approval Date: June 20 2006 IRE Expiration Date: June 19, 2007 STANFORD SAMPLE CONSENT FORM Please

More information

PRISM: PROGESTERONE IN EARLY PREGNANCY BLEEDING

PRISM: PROGESTERONE IN EARLY PREGNANCY BLEEDING Participant Information Sheet PRISM: PROGESTERONE IN EARLY PREGNANCY BLEEDING LOCAL RESEARCH TEAM PRINCIPAL INVESTIGATOR: Ingrid Granne RESEARCH MIDWIVES: Nicola Higgins, Sarah Harding TELEPHONE: 01865

More information

Essentials of RESEARCH GOVERNANCE

Essentials of RESEARCH GOVERNANCE Promoting Good Practice in Research Essentials of RESEARCH GOVERNANCE Information for Researchers, Students and Support Staff involved in Health & Social Care Research 2005 Reproduced with the permission

More information

Carpal Tunnel Syndrome

Carpal Tunnel Syndrome Carpal Tunnel Syndrome Information for Patients Gateshead Upper Limb Unit Page 1 of 6 What is the carpal tunnel? The wrist consists of 8 small bones called carpal bones. A ligament ( also called retinaculum)

More information

Protecting women and babies with anti-d Immunoglobulin

Protecting women and babies with anti-d Immunoglobulin Protecting women and babies with anti-d Immunoglobulin Blood Groups Just as every human being is unique, so are the factors in your blood. People can belong to one of four blood groups, A, B, AB and O,

More information

The Care Record Guarantee Our Guarantee for NHS Care Records in England

The Care Record Guarantee Our Guarantee for NHS Care Records in England The Care Record Guarantee Our Guarantee for NHS Care Records in England Introduction In the National Health Service in England, we aim to provide you with the highest quality of healthcare. To do this,

More information

Imaging Markers of Brain Network Dysfunction in Multiple Sclerosis

Imaging Markers of Brain Network Dysfunction in Multiple Sclerosis Faculty of Medicine & Health Sciences School of Medicine Radiological Sciences Research Group The University of Nottinham University Park Nottingham NG7 2RD t: +44 (0)115 823 0018 f: +44 (0)115 823 0004

More information

Interferon treatment for your cutaneous T-cell lymphoma (CTCL)

Interferon treatment for your cutaneous T-cell lymphoma (CTCL) Interferon treatment for your cutaneous T-cell lymphoma (CTCL) You have been prescribed the medicine interferon alpha-2a, also known by its brand name Roferon -A, for the treatment of your cutaneous T-cell

More information

A Guide to Clinical Trials

A Guide to Clinical Trials A Guide to Clinical Trials For young people with cancer and their parents Children s Cancer and Leukaemia Group www.cclg.org.uk Original booklet produced in conjunction with the CCLG Patient Advocacy Committee.

More information

HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA CONSENT TO PARTICIPATE IN A RESEARCH STUDY AND RESEARCH SUBJECT HIPAA AUTHORIZATION

HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA CONSENT TO PARTICIPATE IN A RESEARCH STUDY AND RESEARCH SUBJECT HIPAA AUTHORIZATION CONSENT TO PARTICIPATE IN A RESEARCH STUDY AND RESEARCH SUBJECT HIPAA AUTHORIZATION Protocol Title: A5322, Version 2.0, 01/28/15 Long-term Follow-up of Older HIV-infected Adults in the ACTG: Addressing

More information

PROCEDURE- SPECIFIC INFORMATION FOR PATIENTS

PROCEDURE- SPECIFIC INFORMATION FOR PATIENTS The British Association of Urological Surgeons 35-43 Lincoln s Inn Fields London WC2A 3PE Phone: Fax: Website: E- mail: +44 (0)20 7869 6950 +44 (0)20 7404 5048 www.baus.org.uk admin@baus.org.uk PROCEDURE-

More information

Clinical Trial Compensation Guidelines

Clinical Trial Compensation Guidelines Clinical Trial Compensation Guidelines Preface These guidelines contain two distinct sections: Phase I Clinical Trials Compensation Guidelines Phases II, III and IV Clinical Trials Compensation Guidelines

More information

STROKE SERIES SS10. Understanding thrombolysis treatment For stroke

STROKE SERIES SS10. Understanding thrombolysis treatment For stroke STROKE SERIES SS10 Understanding thrombolysis treatment For stroke Chest Heart & Stroke Scotland improves the quality of life for people in Scotland affected by chest, heart and stroke illness, through

More information

SUGGESTIONS & REQUIREMENTS For Medical Power of Attorney & Completing the Texas Will to Live Form

SUGGESTIONS & REQUIREMENTS For Medical Power of Attorney & Completing the Texas Will to Live Form SUGGESTIONS & REQUIREMENTS For Medical Power of Attorney & Completing the Texas Will to Live Form 1. This Medical Power of Attorney (also known as the Health Care Agent Designation Form) allows you to

More information

Tesco Private Healthcare Plan. Effective from 1 March 2016. Administered by Bupa. bupa.co.uk

Tesco Private Healthcare Plan. Effective from 1 March 2016. Administered by Bupa. bupa.co.uk Tesco Private Healthcare Plan Effective from 1 March 2016 Administered by Bupa bupa.co.uk This is page 1 of 10 which should be read together in full. These pages are for the Tesco Private Healthcare Plan

More information

Long term observational study for multiple sclerosis patients using fingolimod

Long term observational study for multiple sclerosis patients using fingolimod Investigator: Dr Matthew Jackson (Consultant Neurologist) Centre number: 814 Contact for queries If you have any questions about this study, you can contact: Daytime: Elspeth Wolfenden on 01494 734312

More information

1. General Information About The Mitochondrial Disease Biobank

1. General Information About The Mitochondrial Disease Biobank Name and Clinic Number IRB # 09-002265 00 Consent form approved November 6, 2013; This consent valid through August 6, 2014; 1. General Information About The Mitochondrial Disease Biobank Study Title:

More information

CONSENT FORM TEMPLATE. Derivation and Distribution of Induced Pluripotent Stem (ips) Cell Lines Created from Donor Specimens

CONSENT FORM TEMPLATE. Derivation and Distribution of Induced Pluripotent Stem (ips) Cell Lines Created from Donor Specimens CONSENT FORM TEMPLATE Derivation and Distribution of Induced Pluripotent Stem (ips) Cell Lines Created from Donor Specimens INTRODUCTION We invite you to take part in a research study at [name of research

More information

INFORMATION LEAFLET. If anything is not clear, or if you would like more information, please

INFORMATION LEAFLET. If anything is not clear, or if you would like more information, please BIO INFOBK 1492 0410:Layout 1 21/04/2010 15:24 Page 1 INFORMATION LEAFLET You are being invited to take part in a major medical research project called UK Biobank. The purpose of UK Biobank is to set up

More information

Research & Development Guidance for Students

Research & Development Guidance for Students Research & Development Guidance for Students 2 Contents Introduction 3 Understanding the Research Approval Process 3 Is My Project Audit, Research or Something Else 4 What Next? 4 R&D Step by step Guide

More information

Deep vein thrombosis (DVT)

Deep vein thrombosis (DVT) Deep vein thrombosis (DVT) Normally your blood moves freely throughout the body without any problems. However, if a blood clot forms in a vein it can stop your blood flowing properly. A clot that forms

More information

PRACTICE INFORMATION SHEET

PRACTICE INFORMATION SHEET PRACTICE INFORMATION SHEET Study title A feasibility study for a cluster randomised trial of text messaging reminders for influenza vaccine in patients under 65 in clinical risk groups in English primary

More information

National Emphysema Treatment Trial (NETT) Consent for Screening and Patient Registry

National Emphysema Treatment Trial (NETT) Consent for Screening and Patient Registry National Emphysema Treatment Trial (NETT) Consent for Screening and Patient Registry Instructions: This consent statement is to be signed and dated by the patient in the presence of a certified study staff

More information

National Hospital for Neurology and Neurosurgery. Flow-diverting stents (in the treatment of cerebral aneurysms) Lysholm Department of Neuroradiology

National Hospital for Neurology and Neurosurgery. Flow-diverting stents (in the treatment of cerebral aneurysms) Lysholm Department of Neuroradiology National Hospital for Neurology and Neurosurgery Flow-diverting stents (in the treatment of cerebral aneurysms) Lysholm Department of Neuroradiology If you would like this document in another language

More information

Ultrasound Guided Liver Biopsy

Ultrasound Guided Liver Biopsy Ultrasound Guided Liver Biopsy Patient Information Author ID: N Prasad and G Banait Leaflet Number: End 006 Name of Leaflet: Ultrasound Guided Liver Biopsy Date Produced: March 2014 Review Date: March

More information

National Hospital for Neurology and Neurosurgery. Muscle biopsy Centre for Neuromuscular Diseases

National Hospital for Neurology and Neurosurgery. Muscle biopsy Centre for Neuromuscular Diseases National Hospital for Neurology and Neurosurgery Muscle biopsy Centre for Neuromuscular Diseases If you would like this document in another language or format or if you require the services of an interpreter

More information

HELP SAVE A LIFE DONATE YOUR CORD BLOOD

HELP SAVE A LIFE DONATE YOUR CORD BLOOD HELP SAVE A LIFE DONATE YOUR CORD BLOOD University Hospitals of Leicester Anthony Nolan Cord Blood Donation Programme Did you know that following the safe birth of your baby, you could save a person s

More information

RESEARCH PARTICIPANT INFORMED CONSENT AND PRIVACY AUTHORIZATION FORM

RESEARCH PARTICIPANT INFORMED CONSENT AND PRIVACY AUTHORIZATION FORM Patient I.D. Plate RESEARCH PARTICIPANT INFORMED CONSENT AND PRIVACY AUTHORIZATION FORM Protocol Title: Application No.: Sponsor: The National Simulation Study: Evaluating Simulated Clinical Experiences

More information

Betaferon (interferon beta 1b)

Betaferon (interferon beta 1b) Betaferon (interferon beta 1b) What is Betaferon? Betaferon (interferon beta-1b) is a type of medicine known as an interferon, which is used to treat MS. Interferons are proteins found naturally in the

More information

CT guided lung needle biopsy

CT guided lung needle biopsy Patient s guide and agreement to consent form CT guided lung needle biopsy Patient s guide and agreement to consent form 1 Patient s guide and agreement to consent form This information booklet has been

More information

Dyspepsia: Management of dyspepsia in adults in primary care

Dyspepsia: Management of dyspepsia in adults in primary care Dyspepsia: Management of dyspepsia in adults in primary care Information for the public Draft for consultation, February, 2004 If you wish to comment on the recommendations, please make your comments on

More information

What is renal anaemia?

What is renal anaemia? What is renal anaemia? A guide for patients and carers Delivering the best in care UHB is a no smoking Trust To see all of our current patient information leaflets please visit www.uhb.nhs.uk/patient-information-leaflets.htm

More information

WEB intracranial aneurysm device for treating cerebral aneurysms

WEB intracranial aneurysm device for treating cerebral aneurysms WEB intracranial aneurysm device for treating cerebral aneurysms Information for patients This booklet explains how the WEB device is used to treat cerebral (brain) aneurysms, and the benefits and risks

More information

SHARED CARE PRESCRIBING GUIDELINE SULFASALAZINE (SALAZOPYRIN EN-TABS ) IN ADULT PATIENTS WITH RHEUMATOID ARTHRITIS DOCUMENT DETAILS

SHARED CARE PRESCRIBING GUIDELINE SULFASALAZINE (SALAZOPYRIN EN-TABS ) IN ADULT PATIENTS WITH RHEUMATOID ARTHRITIS DOCUMENT DETAILS SHARED CARE PRESCRIBING GUIDELINE SULFASALAZINE (SALAZOPYRIN EN-TABS ) IN ADULT PATIENTS WITH RHEUMATOID ARTHRITIS DOCUMENT DETAILS Document type Shared Care Prescribing Guideline Document name Shared

More information

Paracetamol apollo +9191 46 950 950. Paracetamol apollo +9191 46 950 950. Paracetamol

Paracetamol apollo +9191 46 950 950. Paracetamol apollo +9191 46 950 950. Paracetamol Paracetamol apollo +9191 46 950 950 Paracetamol apollo +9191 46 950 950 Paracetamol CAS Number : 103-90-2 Molecular Weight : 151.17 g/mol Molecular Formula : C8H9NO2 Systematic (IUPAC) : N-(4- hydroxyphenyl)ethanamide

More information

What You Need to Know About Lung Cancer Immunotherapy

What You Need to Know About Lung Cancer Immunotherapy What You Need to Know About Lung Cancer Immunotherapy Lung.org/immunotherapy What is immunotherapy? Immunotherapy for cancer, sometimes called immune-oncology, is a type of medicine that treats cancer

More information

Bupa Schools Scheme Looking after what s most important

Bupa Schools Scheme Looking after what s most important Provided by Bupa Schls Scheme Lking after what s most important bupa.co.uk/schlscheme The subscription rate is 67.50 per child each term and applies for membership year 1 September 2015 to 31 August 2016.

More information

biologics for the treatment of psoriasis

biologics for the treatment of psoriasis How to contact us The Psoriasis Association Dick Coles House 2 Queensbridge Northampton NN4 7BF tel: 08456 760 076 (01604) 251 620 fax: (01604) 251 621 email: mail@psoriasis-association.org.uk www.psoriasis-association.org.uk

More information

PARTICIPANT INFORMATION AND CONSENT FORM

PARTICIPANT INFORMATION AND CONSENT FORM PARTICIPANT INFORMATION AND CONSENT FORM STUDY TITLE: Reducing long-term disability related to pain: A randomised controlled trial of the Pain Disability Prevention Programme (PDP) in the Irish health

More information

Oxford University Hospitals. NHS Trust. Department of Neurology Natalizumab (Tysabri) for Multiple Sclerosis. Information for patients

Oxford University Hospitals. NHS Trust. Department of Neurology Natalizumab (Tysabri) for Multiple Sclerosis. Information for patients Oxford University Hospitals NHS Trust Department of Neurology Natalizumab (Tysabri) for Multiple Sclerosis Information for patients page 2 What is Natalizumab and what is it used for? Natalizumab is an

More information

RESEARCH PARTICIPANT INFORMED CONSENT AND PRIVACY AUTHORIZATION FORM

RESEARCH PARTICIPANT INFORMED CONSENT AND PRIVACY AUTHORIZATION FORM If you are using Epic for this study, fax a copy of the signed consent form to 410-367-7382. Patient I.D. Plate RESEARCH PARTICIPANT INFORMED CONSENT AND PRIVACY AUTHORIZATION FORM Protocol Title: Application

More information

CAUDAL (EPIDURAL) STEROID INJECTION

CAUDAL (EPIDURAL) STEROID INJECTION CAUDAL (EPIDURAL) STEROID INJECTION Information Leaflet Your Health. Our Priority. Page 2 of 5 What is a Caudal Epidural Steroid injection? A caudal epidural injection is an injection of steroid (anti-inflammatory

More information

What is the Surrey Stroke Services Review? Stroke services in Surrey

What is the Surrey Stroke Services Review? Stroke services in Surrey What is the Surrey Stroke Services Review? Stroke services in Surrey A stroke is caused when the blood supply to the brain is interrupted, usually because a blood vessel bursts or is blocked by a clot.

More information

ORAL ANTICOAGULANTS - RIVAROXABAN (XARELTO) FOR DEEP VEIN THROMBOSIS (DVT)

ORAL ANTICOAGULANTS - RIVAROXABAN (XARELTO) FOR DEEP VEIN THROMBOSIS (DVT) ORAL ANTICOAGULANTS - RIVAROXABAN (XARELTO) FOR DEEP VEIN THROMBOSIS (DVT) Information Leaflet Your Health. Our Priority. Page 2 of 6 What Are Anticoagulants And What Do They Do? This information leaflet

More information

Treatments that may be suitable for home administration include:

Treatments that may be suitable for home administration include: WELCOME Thank you for considering having your treatment with Chemo@home. Chemo@home is an innovative service that gives patients the option of having some cancer and other chronic illnesses (such as rheumatoid

More information